Merck & Co., Inc. (MRK)
145.95
+0.76
(+0.52%)
USD |
NYSE |
Oct 16, 16:00
145.62
-0.33
(-0.23%)
After-Hours: 20:00
Merck Cash from Investing (Quarterly) : -5.602B for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.602B |
| March 31, 2026 | -10.21B |
| December 31, 2025 | -11.20B |
| September 30, 2025 | -283.00M |
| June 30, 2025 | -770.00M |
| March 31, 2025 | -1.487B |
| December 31, 2024 | -1.444B |
| September 30, 2024 | -3.845B |
| June 30, 2024 | -1.069B |
| March 31, 2024 | -1.376B |
| December 31, 2023 | 53.00M |
| September 30, 2023 | -334.00M |
| June 30, 2023 | -11.44B |
| March 31, 2023 | -2.359B |
| December 31, 2022 | -1.748B |
| September 30, 2022 | -962.00M |
| June 30, 2022 | -1.077B |
| March 31, 2022 | -1.173B |
| December 31, 2021 | -12.05B |
| September 30, 2021 | -1.061B |
| June 30, 2021 | -2.811B |
| March 31, 2021 | -634.00M |
| December 31, 2020 | -4.778B |
| September 30, 2020 | -2.155B |
| June 30, 2020 | -882.00M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.628B |
| December 31, 2019 | -763.00M |
| September 30, 2019 | 191.00M |
| June 30, 2019 | -2.425B |
| March 31, 2019 | 368.00M |
| December 31, 2018 | 2.178B |
| September 30, 2018 | 1.66B |
| June 30, 2018 | 673.00M |
| March 31, 2018 | -197.00M |
| December 31, 2017 | -58.00M |
| September 30, 2017 | 671.00M |
| June 30, 2017 | -1.127B |
| March 31, 2017 | 3.193B |
| December 31, 2016 | -2.563B |
| September 30, 2016 | -890.00M |
| June 30, 2016 | -1.498B |
| March 31, 2016 | 1.741B |
| December 31, 2015 | -617.00M |
| September 30, 2015 | -61.00M |
| June 30, 2015 | 2.525B |
| March 31, 2015 | -6.605B |
| December 31, 2014 | 7.204B |
| September 30, 2014 | -3.722B |
| June 30, 2014 | -49.00M |
| March 31, 2014 | -3.807B |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -- |
| Eli Lilly & Co. | -15.40B |
| Pfizer Inc. | 2.106B |
| Bristol Myers Squibb Co. | -1.614B |
| Viatris, Inc. | -51.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 5.37B |
| Cash from Financing (Quarterly) | 1.762B |
| Free Cash Flow | 16.06B |
| Free Cash Flow Per Share (Quarterly) | 1.813 |
| Free Cash Flow to Equity (Quarterly) | -312.00M |
| Free Cash Flow to Firm (Quarterly) | 5.505B |
| Free Cash Flow Yield | 4.43% |